About Us

Rebuilding immune cell therapy from the receptor up

First-generation CAR-T validated the modality and built billion-dollar franchises—but its receptor architecture, largely unchanged for nearly three decades, carries embedded limitations: severe toxicities, T-cell exhaustion, poor persistence, relapse, and near-complete failure in solid tumors. These are not clinical setbacks. They are structural design constraints.

Angeles Therapeutics was founded in 2016 to address these constraints at their source. Our proprietary Synthetic Immune Receptor-T (SIR-T™) platform integrates the signaling biology of a physiological T-cell receptor with the HLA-independent targeting flexibility of conventional CARs. The result: a receptor that signals more naturally, persists longer, resists exhaustion, generates less cytokine-driven toxicity, and—crucially—demonstrates meaningful activity in solid tumors where CAR-T has largely failed.

Across multiple in vitro and in vivo models, SIR-T constructs have shown strong anti-tumor activity in both hematologic and solid tumor systems. The architecture supports multi-antigen targeting within a single receptor framework and is adaptable across autologous, allogeneic, in vivo, universal, bispecific, and multispecific formats. Angeles is not a single-asset company—it is a foundational platform for next-generation cell engineering.

Beyond receptor design, Angeles has built an integrated ecosystem: stem-like T-cell enrichment strategies, efficient gene transfer into difficult-to-transduce cells, optimized expansion platforms, pharmacologic toxicity control, suicide switches, and high-sensitivity potency assays. Our global intellectual property estate—spanning more than 200 patent applications across 15 patent families—creates durable protection around both core receptor architectures and enabling platform technologies. 

Angeles Ecosystem capabilities

Physiological signaling: Physiological receptor architecture restores natural signaling, reducing exhaustion and cytokine toxicity

Solid tumor activity: Demonstrated anti-tumor efficacy in solid tumor models where conventional CAR-T has consistently underperformed

Multi-antigen architecture: Single receptor framework supports bispecific and multispecific targeting; intrinsically modular design

Format flexibility: Adaptable across autologous, allogeneic, universal, and in vivo cell therapy formats

Pharmacologic control: Integrated toxicity control and suicide switch systems enable precision safety management

Manufacturing innovation: Optimized gene transfer and expansion platforms engineered for scalability and commercial viability

Cell therapy is entering its second wave. First-generation CAR-T proved commercial viability but exposed the limits of its original design. Angeles is positioned to lead the transition through architectural innovation—unlocking the next decade of cell therapy growth.